<?xml version='1.0' encoding='utf-8'?>
<document id="23410991"><sentence text="Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH."><entity charOffset="17-27" id="DDI-PubMed.23410991.s1.e0" text="Rifampicin" /><entity charOffset="114-123" id="DDI-PubMed.23410991.s1.e1" text="Isoniazid" /><pair ddi="false" e1="DDI-PubMed.23410991.s1.e0" e2="DDI-PubMed.23410991.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23410991.s1.e0" e2="DDI-PubMed.23410991.s1.e1" /></sentence><sentence text="Rifampicin (RIF), a vital constituent of antitubercular therapy, hydrolyzes at the acidic pH of the stomach"><entity charOffset="0-10" id="DDI-PubMed.23410991.s2.e0" text="Rifampicin" /><entity charOffset="12-15" id="DDI-PubMed.23410991.s2.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.23410991.s2.e0" e2="DDI-PubMed.23410991.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23410991.s2.e0" e2="DDI-PubMed.23410991.s2.e1" /></sentence><sentence text=" The degradation is further enhanced by its interaction with Isoniazid (INH)"><entity charOffset="61-70" id="DDI-PubMed.23410991.s3.e0" text="Isoniazid" /><entity charOffset="72-75" id="DDI-PubMed.23410991.s3.e1" text="INH" /><pair ddi="false" e1="DDI-PubMed.23410991.s3.e0" e2="DDI-PubMed.23410991.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23410991.s3.e0" e2="DDI-PubMed.23410991.s3.e1" /></sentence><sentence text=" Extent of RIF decomposition, in the presence and absence of INH, was determined at pH 1"><entity charOffset="61-64" id="DDI-PubMed.23410991.s4.e0" text="INH" /><entity charOffset="11-13" id="DDI-PubMed.23410991.s4.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.23410991.s4.e1" e2="DDI-PubMed.23410991.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23410991.s4.e1" e2="DDI-PubMed.23410991.s4.e0" /></sentence><sentence text="2 (pH of empty stomach) at 37Â°C for 4 h (maximum stomach residence time)" /><sentence text=" Both the drugs decomposed at gastric pH (26" /><sentence text="5% and 1" /><sentence text="43% for RIF and INH respectively)"><entity charOffset="8-10" id="DDI-PubMed.23410991.s8.e0" text="RIF" /><entity charOffset="16-18" id="DDI-PubMed.23410991.s8.e1" text="INH" /><pair ddi="false" e1="DDI-PubMed.23410991.s8.e0" e2="DDI-PubMed.23410991.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23410991.s8.e0" e2="DDI-PubMed.23410991.s8.e1" /></sentence><sentence text=" Considering that solid lipid nanoparticles (SLNs) avert drug-drug interaction and also drug degradation, we incorporated RIF into SLNs"><entity charOffset="122-124" id="DDI-PubMed.23410991.s9.e0" text="RIF" /></sentence><sentence text=" Latter reduced its degradation to ~9% (from 26" /><sentence text="50% when present alone) and to ~20% (from 48" /><sentence text="81% when INH was also present)"><entity charOffset="9-12" id="DDI-PubMed.23410991.s12.e0" text="INH" /></sentence><sentence text=" Subsequent to this, we also incorporated INH into SLNs and the percent degradation of RIF in this combination (RIF SLNs+INH SLNs) further reduced to 12"><entity charOffset="87-89" id="DDI-PubMed.23410991.s13.e0" text="RIF" /><entity charOffset="112-114" id="DDI-PubMed.23410991.s13.e1" text="RIF" /><entity charOffset="42-44" id="DDI-PubMed.23410991.s13.e2" text="INH" /><entity charOffset="121-123" id="DDI-PubMed.23410991.s13.e3" text="INH" /><pair ddi="false" e1="DDI-PubMed.23410991.s13.e2" e2="DDI-PubMed.23410991.s13.e2" /><pair ddi="false" e1="DDI-PubMed.23410991.s13.e2" e2="DDI-PubMed.23410991.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23410991.s13.e2" e2="DDI-PubMed.23410991.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23410991.s13.e2" e2="DDI-PubMed.23410991.s13.e3" /><pair ddi="false" e1="DDI-PubMed.23410991.s13.e0" e2="DDI-PubMed.23410991.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23410991.s13.e0" e2="DDI-PubMed.23410991.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23410991.s13.e0" e2="DDI-PubMed.23410991.s13.e3" /><pair ddi="false" e1="DDI-PubMed.23410991.s13.e1" e2="DDI-PubMed.23410991.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23410991.s13.e1" e2="DDI-PubMed.23410991.s13.e3" /></sentence><sentence text="35%" /><sentence text=" Furthermore, the degradation of INH in combination with RIF also reduced significantly from 13"><entity charOffset="33-36" id="DDI-PubMed.23410991.s15.e0" text="INH" /><entity charOffset="57-59" id="DDI-PubMed.23410991.s15.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.23410991.s15.e0" e2="DDI-PubMed.23410991.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23410991.s15.e0" e2="DDI-PubMed.23410991.s15.e1" /></sentence><sentence text="2% to 2" /><sentence text="7% when both the drugs were encapsulated individually within SLNs" /><sentence text=" Study therefore highlights the need to develop combinations of antitubercular drugs (ATDs) with caution and also establishes the usefulness of nanoparticulate technology to avoid drug-drug interaction" /><sentence text="" /></document>